scholarly journals Tu1182 PREDICTIVE FACTORS FOR THE ERADICATION OF ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS UNDERGOING ENDOSCOPIC BAND LIGATION.

2018 ◽  
Vol 87 (6) ◽  
pp. AB558
Author(s):  
Daniele Tavano ◽  
Stefano Pontone ◽  
Antonietta Lamazza ◽  
Rossella Palma ◽  
Cristina Panetta ◽  
...  
2018 ◽  
Author(s):  
J Pereira Rodrigues ◽  
S Fernandes ◽  
L Proença ◽  
M Sousa ◽  
JC Silva ◽  
...  

2010 ◽  
Vol 9 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Rosa María Pérez-Ayuso ◽  
Sebastián Valderrama ◽  
Manuel Espinoza ◽  
Antonio Rollán ◽  
René Sánchez ◽  
...  

2018 ◽  
Vol 68 ◽  
pp. S748
Author(s):  
J. Rodrigues ◽  
S. Fernandes ◽  
L. Proença ◽  
M. Sousa ◽  
J.C. Silva ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Seung Woon Park ◽  
Yeon Seok Seo ◽  
Han Ah Lee ◽  
Sang Jung Park ◽  
Tae Hyung Kim ◽  
...  

Background and Aims. Cardiac varices (CVs) in patients with type 1 gastroesophageal varices (GOV1s) usually disappear with treatment for esophageal varices (EVs) by endoscopic injection sclerotherapy (EIS). However, whether this applies to patients treated with endoscopic band ligation (EBL) for EVs remains unclear. We evaluated the effect of EVs eradication by EBL on CVs.Methods. We included cirrhotic patients whose EVs had been eradicated using EBL and excluded those who had been treated using EIS, those who had received endoscopic therapy for CVs, and those who were combined with hepatocellular carcinoma.Results. A total of 123 patients were enrolled. The age was 59.7 ± 11.7 years, and 96 patients (78.0%) were men. Thirty-eight patients (30.9%) had EVs only, while 85 (69.1%) had GOV1s. After EVs eradication, the CVs disappeared in 55 patients (64.7%). EVs recurred in 40 patients, with recurrence rates at 1, 2, and 3 years of 16.0%, 29.6%, and 35.6%, respectively, the recurrence being more frequent in patients who had undergone EBL for secondary prophylaxis and in those with persisting CVs after EVs eradication (P=0.003).Conclusions. CVs frequently disappeared when EVs were eradicated using EBL in patients with GOV1s. Persistence of CVs after EVs eradication by EBL was associated with EVs recurrence.


Gut ◽  
2017 ◽  
Vol 67 (12) ◽  
pp. 2156-2168 ◽  
Author(s):  
Yong Lv ◽  
Xingshun Qi ◽  
Chuangye He ◽  
Zhengyu Wang ◽  
Zhanxin Yin ◽  
...  

ObjectiveLimited data are available on the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT). This study aimed to compare transjugular intrahepatic portosystemic shunt (TIPS) with covered stents versus endoscopic band ligation (EBL) plus propranolol for the prevention of variceal rebleeding among patients with cirrhosis and PVT.DesignConsecutive cirrhotic patients (94% Child-Pugh class A or B) with PVT who had variceal bleeding in the past 6 weeks were randomly assigned to TIPS group (n=24) or EBL plus propranolol group (EBL+drug, n=25), respectively. Primary endpoint was variceal rebleeding. Secondary endpoints included survival, overt hepatic encephalopathy (OHE), portal vein recanalisation and rethrombosis, other complications of portal hypertension and adverse events.ResultsDuring a median follow-up of 30 months in both groups, variceal rebleeding was significantly less frequent in the TIPS group (15% vs 45% at 1 year and 25% vs 50% at 2 years, respectively; HR=0.28, 95% CI 0.10 to 0.76, p=0.008), with a significantly higher portal vein recanalisation rate (95% vs 70%; p=0.03) and a relatively lower rethrombosis rate (5% vs 33%; p=0.06) compared with the EBL+drug group. There were no statistically significant differences in survival (67% vs 84%; p=0.152), OHE (25% vs 16%; p=0.440), other complications of portal hypertension and adverse events between groups.ConclusionCovered TIPS placement in patients with PVT and moderately decompensated cirrhosis was more effective than EBL combined with propranolol for the prevention of rebleeding, with a higher probability of PVT resolution without increasing the risk of OHE and adverse effects, but this benefit did not translate into improved survival.Trial registration numberClinicalTrials.gov: NCT01326949.


2007 ◽  
Vol 65 (5) ◽  
pp. AB107
Author(s):  
Marcus M. Santos ◽  
Rodrigo Azevedo Rodrigues ◽  
Luciano Lenz ◽  
Frank Nakao ◽  
Maria Rachel S. Rohr ◽  
...  

2008 ◽  
Vol 67 (5) ◽  
pp. AB189
Author(s):  
Gustavo O. Luz ◽  
Fauze Maluf-Filho ◽  
Sergio E. Matuguma ◽  
Fabio Y. Hondo ◽  
Spencer Cheng ◽  
...  

1993 ◽  
Vol 39 (2) ◽  
pp. 181-185 ◽  
Author(s):  
Paul A. Johnson ◽  
Donald R. Campbell ◽  
Clark W. Antonson ◽  
Allan P. Weston ◽  
Frederick N. Shuler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document